4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Inovio Pharmaceuticals, Inc. (INO) operates in the Biotechnology industry and is headquartered in Plymouth Meeting, United States with about 112 employees. Its market capitalization is roughly $97 million. In the fiscal year ended 2025-12-31, INO reported $0M in revenue and ($85M) in net income.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $1M | $10M | — |
| Operating Income (EBIT) | ($87M) | ($112M) | ($133M) | ($268M) | — |
| Net Income | ($85M) | ($107M) | ($135M) | ($280M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($22M) | ($18M) | ($21M) | ($23M) | ($25M) | — |
| Net Income | ($20M) | $4M | ($46M) | ($24M) | ($20M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $74M | $113M | $171M | $348M | — |
| Total Liabilities | $50M | $45M | $54M | $126M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INO viewer.
About TickerBase · Data methodology & sources